Safety and Efficacy of Mitapivat (AG-348), an Oral Activator of Pyruvate Kinase R, in Subjects with Sickle Cell Disease: A Phase 2, Open-Label Study (ESTIMATE)

Authors
Category Primary study
JournalBlood
Year 2021
This article has no abstract
Epistemonikos ID: 59e11c145f0ba8be7fdfaa23f855910cecdff3e0
First added on: Feb 13, 2025